Advertisement

International Journal of Clinical Pharmacy

, Volume 41, Issue 5, pp 1159–1165 | Cite as

Iatrogenic hypoglycemia–related hospital admissions identified through databases: economic burden and causes

  • Tiphaine Richard
  • Romane Issa
  • Emmanuel Andres
  • Bénédicte Gourieux
  • Nathalie Jeandidier
  • Bruno MichelEmail author
Research Article
  • 110 Downloads

Abstract

Background Hypoglycemia is an acute and frequent complication of diabetes. Objectives To assess the number of hospital admissions due to iatrogenic hypoglycemia in Alsace (France) over a year, to estimate the associated economic burden and to identify causes. Method A retrospective analysis was performed using data extracted from hospital databases. Costs were calculated from French official tariffs. Setting 31 public and private hospitals. A review of the medical records of patients with iatrogenic hypoglycemia-related hospital admissions was performed at the University Hospital of Strasbourg. Main outcome measures Hypoglycemia–related hospital admissions: number, costs and causes. Results Out of 42,381 hospitalizations, 147 iatrogenic hypoglycemia–related hospital admissions (0.4%) were identified; 41 patients with type 1 diabetes mellitus and 106 with type 2. The total cost associated to the 147 events was € 407,441. The median cost per patient was € 1,224.6 [563.0–2,505.7 (interquartile range)] for type 1 diabetes mellitus and € 3,670.9 [2,505.7–3,670.9] for type 2. Forty-six patients over the 147 were coming from the University Hospital of Strasbourg. In this hospital, the most common origin of the hypoglycemia was missed meals (n = 7), the second was a mismatch between antidiabetic medicines and carbohydrate intake (n = 6), the third was an incorrect use of antidiabetic medicines (n = 5). Conclusions 147 hospitalizations due to iatrogenic hypoglycemia were identified with an estimated global cost of € 407,441. Optimizing therapy with low-risk hypoglycemic medicines, improving access to continuous glucose monitoring systems and offering adequate education, could help address the causes of hypoglycemia.

Keywords

France Hospital admission Iatrogenic hypoglycemia Inappropriate prescription Therapeutic education 

Notes

Acknowledgements

The authors wish to acknowledge Dr. Sylvie Fontanel and Daouda Camara from the ARS Grand Est (extraction of the data from regional PMSI database), Dr. Gabriel Nisand from the PMSI Department of the University Hospital of Strasbourg (access of the patients’ medical records) and Dr. Valérie Leray for proofreading and linguistic review of the manuscript.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Conflicts of interest

The authors report no conflict of interest relevant to the subject of this article.

References

  1. 1.
    Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol. 2014;10:711–22.CrossRefGoogle Scholar
  2. 2.
    Cariou B, Fontaine P, Eschwege E, Lièvre M, Gouet D, Huet D, et al. Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study. Diabetes Metab. 2015;41:116–25.CrossRefGoogle Scholar
  3. 3.
    Hammer M, Lammert M, Mejías SM, Kern W, Frier BM. Costs of managing severe hypoglycaemia in three European countries. J Med Econ. 2009;12:281–90.CrossRefGoogle Scholar
  4. 4.
    Heng C, Rybarczyk-Vigouret MC, Michel B. Anticoagulant-related hospital admissions: serious adverse reactions identified through hospital databases. Pharmacoepidemiol Drug Saf. 2015;24:144–51.CrossRefGoogle Scholar
  5. 5.
    Holbrook T, Tang Y, Das R, Shankar RR, Tunceli K, Williams J, et al. Direct medical costs of severe hypoglycaemic events in patients with type 2 diabetes in England: a retrospective database study. Int J Clin Pract. 2017;71.Google Scholar
  6. 6.
    Ward A, Alvarez P, Vo L, Martin S. Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012). J Med Econ. 2014;17:176–83.CrossRefGoogle Scholar
  7. 7.
    Aronson R, Galstyan G, Goldfracht M, Al Sifri S, Elliott L, Khunti K. Direct and indirect health economic impact of hypoglycaemia in a global population of patients with insulin-treated diabetes. Diabetes Res Clin Pract. 2018;138:35–43.CrossRefGoogle Scholar
  8. 8.
    Iqbal A, Heller SR. The role of structured education in the management of hypoglycaemia. Diabetologia. 2018;61(4):751–60.CrossRefGoogle Scholar
  9. 9.
    Aguiar PM, de Brito GC, de Lima TM, Santos APAL, Lyra DP, Storpirtis S. Investigating sources of heterogeneity in randomized controlled trials of the effects of pharmacist interventions on glycemic control in type 2 diabetic patients: a systematic review and meta-analysis. PLoS ONE. 2016;11:e0150999.CrossRefGoogle Scholar
  10. 10.
    Wong CW. Avoiding hypoglycaemia: a new target of care for elderly diabetic patients. Hong Kong Med J Xianggang Yi Xue Za Zhi Hong Kong Acad Med. 2015;21:444–54.Google Scholar
  11. 11.
    Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.CrossRefGoogle Scholar
  12. 12.
    ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.CrossRefGoogle Scholar
  13. 13.
    Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.CrossRefGoogle Scholar
  14. 14.
    Halimi S. Severe hypoglycaemia the “tip of the iceberg”: an underestimated risk in both type 1 and type 2 diabetic patients. Diabetes Metab. 2015;41:105–6.CrossRefGoogle Scholar
  15. 15.
    Lau IT, Lee KF, So WY, Tan K, Yeung VTF. Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2017;10:273–84.CrossRefGoogle Scholar
  16. 16.
    Ritzel R, Roussel R, Bolli GB, Vinet L, Brulle-Wohlhueter C, Glezer S, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes. Diabetes Obes Metab. 2015;17:859–67.CrossRefGoogle Scholar
  17. 17.
    Karamat MA, Dar S, Bellary S, Tahrani AA. Clinical and cost implications of insulin degludec in patients with type 1 diabetes and problematic hypoglycemia: a quality improvement project. Diabetes Ther Res Treat Educ Diabetes Relat Disord. 2018;9:839–49.Google Scholar
  18. 18.
    Aberer F, Hajnsek M, Rumpler M, Zenz S, Baumann PM, Elsayed H, et al. Evaluation of subcutaneous glucose monitoring systems under routine environmental conditions in patients with type 1 diabetes. Diabetes Obes Metab. 2017;19:1051–5.CrossRefGoogle Scholar
  19. 19.
    Wild SH, Hanley J, Lewis SC, McKnight JA, McCloughan LB, Padfield PL, et al. Supported telemonitoring and glycemic control in people with type 2 diabetes: the telescot diabetes pragmatic multicenter randomized controlled trial. PLoS Med [Internet]. 2016 [cited 2016 Aug 22];13. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961438/.
  20. 20.
    Hermanns N, Kulzer B, Krichbaum M, Kubiak T, Haak T. Long-term effect of an education program (HyPOS) on the incidence of severe hypoglycemia in patients with type 1 diabetes. Diabetes Care. 2010;33:e36.CrossRefGoogle Scholar
  21. 21.
    Mathur S, Zammitt NN, Frier BM. Optimal glycaemic control in elderly people with type 2 diabetes: What does the evidence say? Drug Saf. 2015;38:17–32.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of PharmacyUniversity Hospital of Strasbourg, NHC, Service de PharmacieStrasbourg CedexFrance
  2. 2.Faculty of PharmacyUniversity of StrasbourgStrasbourgFrance
  3. 3.Department of Internal MedicineUniversity Hospital of StrasbourgStrasbourgFrance
  4. 4.Department of Endocrinology and DiabetesUniversity Hospital of StrasbourgStrasbourgFrance
  5. 5.Laboratory of Neuro-cardiovascular Pharmacology and Toxicology EA7296University of StrasbourgStrasbourgFrance

Personalised recommendations